Bioamber Inc (NYSE:BIOA) Sentiment Worsened, Because

May 26, 2018 - By Rodney Autry

BioAmber Inc. (NYSE:BIOA) Logo

Sentiment for Bioamber Inc (NYSE:BIOA)

Bioamber Inc (NYSE:BIOA) institutional sentiment decreased to 0.57 in 2017 Q4. Its down -0.04, from 0.61 in 2017Q3. The ratio turned negative, as 8 funds increased or started new stock positions, while 14 sold and decreased positions in Bioamber Inc. The funds in our partner’s database now hold: 2.55 million shares, down from 7.40 million shares in 2017Q3. Also, the number of funds holding Bioamber Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 8 Increased: 4 New Position: 4.

BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various chemical market clients primarily in the United States and Canada. The company has market cap of $. The Company’s proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into chemicals that are replacements for petroleum-derived chemicals. It currently has negative earnings. The companyÂ’s bio-succinic acid is used in various applications, including plasticizers, polyurethanes, personal care products, resins and coatings, de-icing solutions, PET resins, lubricants, polybutylene succinate, fine chemicals, and food additives.

The stock decreased 58.71% or $0.0182 during the last trading session, reaching $0.0128. About shares traded. BioAmber Inc. (NYSE:BIOA) has declined 98.42% since May 26, 2017 and is downtrending. It has underperformed by 109.97% the S&P500.

Robecosam Ag holds 0.04% of its portfolio in BioAmber Inc. for 1.48 million shares. Bank Of America Corp De owns 951 shares or 0% of their US portfolio. Moreover, Bank Of Montreal Can has 0% invested in the company for 2,000 shares. The New York-based Bank Of New York Mellon Corp has invested 0% in the stock. Blackrock Inc., a New York-based fund reported 131,313 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.